Investigators: Suzanne Angeli, Julie Andersen, Gordon Lithgow

Targeting non-neuronal tissues to slow or halt the progression of Alzheimer’s disease

Previous studies have shown that patients on FDA-approved immunosuppressive drugs have staggeringly low incidence of Alzheimer’s disease compared to the general population, despite these drugs not crossing the brain’s protective sheath – the blood brain barrier. Thus, targeting peripheral (non-neuronal) tissues may be effective in ameliorating the brain symptoms of Alzheimer’s disease. However, no studies have directly addressed this.

We hypothesize that drugs that target non-neuronal tissues are an untapped resource that could slow and even halt the progression of Alzheimer’s disease pathology.